Fatigue in multiple sclerosis – diagnostic problems and selected therapeutic possibilities Review article
Article Sidebar
Published:
Dec 31, 2016
Keywords:
multiple sclerosis, fatigue syndrome, depression
Main Article Content
Abstract
Multiple Sclerosis (MS) is an autoimmune, chronic disease of the central nervous system. The characteristic feature of the disease is a great heterogeneity of clinical symptoms and course. It leads to reduction in physical efficiency and cognitive-behavioral dysfunction. Fatigue is one of the most common complaint reported by patients with MS. The patomechanism of fatigue syndrome in MS has not been clearly explained and treatment is major problem. The recommended treatment dedicated for patients with fatigue in MS are pharmacological and nonpharmacological therapies. The importance of treating the symptoms that may increase fatigue is emphasized (increased body temperature, depression, anxiety, sleep disturbances, hypertonia).
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Calabrese P.: Neuropsychology of multiple sclerosis. J. Neurol. 2006; 253(supl. 1): i10-i15.
2. Chwastiac L.A., Gibbons L.E., Ehde D.M. et al.: Fatigue and psychiatric illness in large community sample of persons with multiple sclerosis. J. Psychosom. Res. 2005; 59(5): 291-298.
3. Feinstein A.: The neuropsychiatry of multiple sclerosis. Can. J. Psychiatry 2004; 49: 157-163.
4. Maciejek Z., Wawrzyniak S.: Objawy kliniczne i przebieg choroby. W: Losy J. (red.): Stwardnienie rozsiane. Wydawnictwo Czelej, Lublin 2013.
5. Béthoux F.: Fatigue and multiple sclerosis. Ann. Readapt. Med. Phys. 2006; 49: 355-360.
6. Kumor K., Pierzchała K.: Problem zmęczenia w chorobach neurologicznych. Wiad. Lek. 2006; 59(9-10): 685-691.
7. Losy J.: Zmęczenie w stwardnieniu rozsianym. Farmakoter. Psych. Neurol. 2005; 3: 279-282.
8. Greim B., Engel C., Apel A. et al.: Fatigue in neuroimmunological diseases. J. Neurol. 2007; 254(supl. 2): 102-106.
9. Weiland T.J., Jelinek G.A., Marck C.H. et al.: Clinically Significant Fatigue: Prevalence and Associated Factor in an International Sample of Adults with Multiple Sclerosis Recruited via the Internet. PloS one 2015; 18: 1-18.
10. Brola W., Fudala M.: Problem zmęczenia w stwardnieniu rozsianym. Prz. Med. Uniw. Rzesz. 2010; 2: 237-243.
11. Szepietowska M.: Procesy pamięciowe u osób chorych na stwardnienie rozsiane. Analiza neuropsychologiczna. Wydawnictwo UMCS, Lublin 2006.
12. Brola W., Ziomek M., Czernicki J.: Zespół zmęczenia w przewlekłych chorobach neurologicznych. Neurol. Neurochir. Pol. 2007; 41(4): 340-349.
13. Zwarts M.J., Bleijenberg G., van Engelen B.G.M.: Clinical neurophysiology of fatigue. Clin. Neurphysiol. 2008; 119: 2-10.
14. Norheim I.B., Jonsson G., Omdal R.: Biological mechanisms of chronic fatigue. Rheumatology 2011; 50: 1009-1018.
15. Kasatkin D.S., Spirin N.N.: Possible Mechanisms of the Formation of Chronic Fatigue Syndrome in the Clinical Picture of Multiple Sclerosis. Neurosci. Behav. Physiol. 2007; 37(3): 215-219.
16. Kos D., Kerckhofs E., Nagels G. et al.: Origin of Fatigue in Multiple Sclerosis: A Review of Literature. Neurorehabil. Neural. Repair. 2008; 22(1): 91-100.
17. van Kessel K., Moss-Morris R.: Understanding multiple sclerosis fatigue: a synthesis of biological and psychological factors. J. Psychosom. Res. 2006; 61: 583-585.
18. Bol Y., Duits A.A., Hupperts Met R.M. et al.: The psychology of fatigue in patients with multiple sclerosis: A review. J. Psychosom. Res. 2009, 66: 3-11.
19. Calabrese M., Rinaldi F., Grossi P. et al.: Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult. Scler. 2010; 16(10): 1220-1228.
20. Niepel G., Tench C.R., Morgan P.S. et al.: Deep gray matter and fatigue in MS. A T1 relaxation time study. J. Neurol. 2006; 253: 896-902.
21. Rinehart J., Hersh E., Issell B. et al.: Phase 1 trial of recombinant human interleukin-1 beta (rthlL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940. Cancer Invest. 1997; 15: 403-410.
22. Greenberg D.B., Gray J.L., Mannix C.M. et al.: Treatment-realted fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J. Pain Symptom. Manage 1993; 8: 193-200.
23. Papanicolaou D.A., Wider R.L., Manolagas S.C. et al.: The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 1998; 128: 127-137.
24. Spath-Schwalbe E., Hansen K., Schmidt F. et al.: Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J. Endocrinol. Metab. 1998; 83: 1573-1579.
25. Fukuda K., Straus S.E., Hickie I. et al.; International Chronic Fatigue Syndrome Study Group: The chronic fatigue syndrome a comprehension approach to its definition and study. Ann. Intern. Med. 1994; 121(12): 953-959.
26. Barak Y., Achiron A.: Cognitive fatigue in multiple sclerosis. Findings from a two-wave screening project. J. Neurol. Sci. 2006; 245: 73-76.
27. Berard J.A., Bowman M., Atkins H.I. et al.: Cognitive fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and hematopoietic stem cell transplantation. J. Neurol. Sci. 2014; 336: 132-137.
28. Walker L.A.S., Berard J.A., Berrigan L.I. et al.: Detecting cognitive fatigue in multiple sclerosis: Method matters. J. Neurol. Sci. 2012; 316: 86-92.
29. Bakshi R.: Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult. Scler. 2003; 9(3): 219-227.
30. Braley T.J., Chervin R.D.: Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep 2010; 33(8): 1061-1067.
31. Dworzańska E., Mitosek-Szewczyk K., Stelmasiak Z.: Zespół zmęczenia w stwardnieniu rozsianym. Neurol. Neurochir. Pol. 2009; 43: 71-76.
32. Selmaj K.: Stwardnienie rozsiane. Termedia, Poznań 2006.
33. Shah A.: Fatigue in Multiple Sclerosis. Phys. Med. Rehabil. Clin. N. Am. 2009; 20: 363-372.
34. Van Schependom J., D’Hooghe M.B., De Schepper M. et al.: Relative contribution of cognitive and physical disability components to quality of life in MS. J. Neurol. Sci. 2014; 336: 116-121.
35. Schapiro R.T.: Managing symptoms of multiple sclerosis. Neurol. Clin. 2005; 23: 177-187.
36. Rosenberg J.H., Shafor R.: Fatigue in multiple sclerosis: a rational approach to evaluation and treatment. Curr. Neurol. Neurosci. Rep. 2005; 5: 140-146.
37. Strober L.B., Arnett P.A.: An examination of four models predicting fatigue in multiple sclerosis. Arch. Clin. Neuropsychol. 2005; 20: 631-646.
38. Feinstein A.: Is there a cognitive signature for multiple sclerosis-related fatigue? MSJ 2015; 21(4): 353-354.
39. Strober L.B.: Fatigue in multiple sclerosis: a look at the role of poor sleep. Front Neurol. 2015; 12(6): 21.
40. Siegert R.J., Abernethy D.A.: Depression in multiple sclerosis: a review. J. Neurol. Neurosurg. Psychiatry 2005; 76: 469-475.
41. Ferreira M.L.C.: Cognitive deficits in multiple sclerosis: a systematic review. Arq. Neuropsiquiatr. 2010; 68(4): 632-641.
42. Pittion-Vouyovitch S., Debouverie M., Guillemin F. et al.: Fatigue in multiple sclerosis is related to disability, depression and quality of live. J. Neurol. Sci. 2006; 243: 39-45.
43. Łabuz-Roszak B., Kubicka-Bączyk K., Pierzchała K. et al.: Jakość życia chorych na stwardnienie rozsiane – związek z cechami klinicznymi choroby, zespołem zmęczenia i objawami depresyjnymi. Psychiatr. Pol. 2013; 46(3): 433-442.
44. Paraprigopoulos T., Ferentinos P., Kouzoupis A. et al.: The neuropsychiatry of multiple sclerosis: Focus on disorders of mood, affect and behaviour. Int. Rev. Psychiatr. 2010; 22(1): 14-21.
45. Jason L., Evans M., Brown M. et al.: Fatigue Scales and Chronic Fatigue Syndrome: Issues of Sensitivity and Specificity. DSQ 2011; 31(1): 1375 (online).
46. Krupp L.B., La Brocca N.G., Muir-Nash J. et al.: The fatigue severity scale: Application to patients with multiple sclerosis and systemic lapus erythematosus. Arc. Neurol. 1989; 46: 1121-1123.
47. Rietberg M.B., Van Wegen E.E.H., Kwakkel G.: Measuring fatigue in patients with multiple sclerosis: reproducibility, responsiveness and concurrent validity of three Dutch self-report questionnaires. Disabil. Rehabil. 2010; 32(22): 1870-1876.
48. Bartosik-Psujek H.: Aktualne zasady terapii stwardnienia rozsianego. Aktualn. Neurol. 2009; 9(2): 126-131.
49. Metz L.M., Patten S.B., Archibald C.J. et al.: The effect of immunomodulatory treatment on multiple sclerosis fatigue. J. Neurol. Neurosurg. Psychiatry 2004; 75(7): 1045-1047.
50. Ziemssen T.: Multiple sclerosis beyond EDSS: depression and fatigue. J. Neurol. Sci. 2009; 277(supl. 1): S37-41.
51. Jongen P.J., Lehnick D., Koeman J. et al.: Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study. J. Neurol. 2014; 261: 1469-1476.
52. Wilken J., Kane R.L., Sullivan L. et al.: Changes in fatigue and cognition in patients with relapsing forms of multiple sclerosis treated with natalizumab. Int. J. MS Care 2013; 15(3): 120-128.
2. Chwastiac L.A., Gibbons L.E., Ehde D.M. et al.: Fatigue and psychiatric illness in large community sample of persons with multiple sclerosis. J. Psychosom. Res. 2005; 59(5): 291-298.
3. Feinstein A.: The neuropsychiatry of multiple sclerosis. Can. J. Psychiatry 2004; 49: 157-163.
4. Maciejek Z., Wawrzyniak S.: Objawy kliniczne i przebieg choroby. W: Losy J. (red.): Stwardnienie rozsiane. Wydawnictwo Czelej, Lublin 2013.
5. Béthoux F.: Fatigue and multiple sclerosis. Ann. Readapt. Med. Phys. 2006; 49: 355-360.
6. Kumor K., Pierzchała K.: Problem zmęczenia w chorobach neurologicznych. Wiad. Lek. 2006; 59(9-10): 685-691.
7. Losy J.: Zmęczenie w stwardnieniu rozsianym. Farmakoter. Psych. Neurol. 2005; 3: 279-282.
8. Greim B., Engel C., Apel A. et al.: Fatigue in neuroimmunological diseases. J. Neurol. 2007; 254(supl. 2): 102-106.
9. Weiland T.J., Jelinek G.A., Marck C.H. et al.: Clinically Significant Fatigue: Prevalence and Associated Factor in an International Sample of Adults with Multiple Sclerosis Recruited via the Internet. PloS one 2015; 18: 1-18.
10. Brola W., Fudala M.: Problem zmęczenia w stwardnieniu rozsianym. Prz. Med. Uniw. Rzesz. 2010; 2: 237-243.
11. Szepietowska M.: Procesy pamięciowe u osób chorych na stwardnienie rozsiane. Analiza neuropsychologiczna. Wydawnictwo UMCS, Lublin 2006.
12. Brola W., Ziomek M., Czernicki J.: Zespół zmęczenia w przewlekłych chorobach neurologicznych. Neurol. Neurochir. Pol. 2007; 41(4): 340-349.
13. Zwarts M.J., Bleijenberg G., van Engelen B.G.M.: Clinical neurophysiology of fatigue. Clin. Neurphysiol. 2008; 119: 2-10.
14. Norheim I.B., Jonsson G., Omdal R.: Biological mechanisms of chronic fatigue. Rheumatology 2011; 50: 1009-1018.
15. Kasatkin D.S., Spirin N.N.: Possible Mechanisms of the Formation of Chronic Fatigue Syndrome in the Clinical Picture of Multiple Sclerosis. Neurosci. Behav. Physiol. 2007; 37(3): 215-219.
16. Kos D., Kerckhofs E., Nagels G. et al.: Origin of Fatigue in Multiple Sclerosis: A Review of Literature. Neurorehabil. Neural. Repair. 2008; 22(1): 91-100.
17. van Kessel K., Moss-Morris R.: Understanding multiple sclerosis fatigue: a synthesis of biological and psychological factors. J. Psychosom. Res. 2006; 61: 583-585.
18. Bol Y., Duits A.A., Hupperts Met R.M. et al.: The psychology of fatigue in patients with multiple sclerosis: A review. J. Psychosom. Res. 2009, 66: 3-11.
19. Calabrese M., Rinaldi F., Grossi P. et al.: Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult. Scler. 2010; 16(10): 1220-1228.
20. Niepel G., Tench C.R., Morgan P.S. et al.: Deep gray matter and fatigue in MS. A T1 relaxation time study. J. Neurol. 2006; 253: 896-902.
21. Rinehart J., Hersh E., Issell B. et al.: Phase 1 trial of recombinant human interleukin-1 beta (rthlL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940. Cancer Invest. 1997; 15: 403-410.
22. Greenberg D.B., Gray J.L., Mannix C.M. et al.: Treatment-realted fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J. Pain Symptom. Manage 1993; 8: 193-200.
23. Papanicolaou D.A., Wider R.L., Manolagas S.C. et al.: The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 1998; 128: 127-137.
24. Spath-Schwalbe E., Hansen K., Schmidt F. et al.: Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J. Endocrinol. Metab. 1998; 83: 1573-1579.
25. Fukuda K., Straus S.E., Hickie I. et al.; International Chronic Fatigue Syndrome Study Group: The chronic fatigue syndrome a comprehension approach to its definition and study. Ann. Intern. Med. 1994; 121(12): 953-959.
26. Barak Y., Achiron A.: Cognitive fatigue in multiple sclerosis. Findings from a two-wave screening project. J. Neurol. Sci. 2006; 245: 73-76.
27. Berard J.A., Bowman M., Atkins H.I. et al.: Cognitive fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and hematopoietic stem cell transplantation. J. Neurol. Sci. 2014; 336: 132-137.
28. Walker L.A.S., Berard J.A., Berrigan L.I. et al.: Detecting cognitive fatigue in multiple sclerosis: Method matters. J. Neurol. Sci. 2012; 316: 86-92.
29. Bakshi R.: Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult. Scler. 2003; 9(3): 219-227.
30. Braley T.J., Chervin R.D.: Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep 2010; 33(8): 1061-1067.
31. Dworzańska E., Mitosek-Szewczyk K., Stelmasiak Z.: Zespół zmęczenia w stwardnieniu rozsianym. Neurol. Neurochir. Pol. 2009; 43: 71-76.
32. Selmaj K.: Stwardnienie rozsiane. Termedia, Poznań 2006.
33. Shah A.: Fatigue in Multiple Sclerosis. Phys. Med. Rehabil. Clin. N. Am. 2009; 20: 363-372.
34. Van Schependom J., D’Hooghe M.B., De Schepper M. et al.: Relative contribution of cognitive and physical disability components to quality of life in MS. J. Neurol. Sci. 2014; 336: 116-121.
35. Schapiro R.T.: Managing symptoms of multiple sclerosis. Neurol. Clin. 2005; 23: 177-187.
36. Rosenberg J.H., Shafor R.: Fatigue in multiple sclerosis: a rational approach to evaluation and treatment. Curr. Neurol. Neurosci. Rep. 2005; 5: 140-146.
37. Strober L.B., Arnett P.A.: An examination of four models predicting fatigue in multiple sclerosis. Arch. Clin. Neuropsychol. 2005; 20: 631-646.
38. Feinstein A.: Is there a cognitive signature for multiple sclerosis-related fatigue? MSJ 2015; 21(4): 353-354.
39. Strober L.B.: Fatigue in multiple sclerosis: a look at the role of poor sleep. Front Neurol. 2015; 12(6): 21.
40. Siegert R.J., Abernethy D.A.: Depression in multiple sclerosis: a review. J. Neurol. Neurosurg. Psychiatry 2005; 76: 469-475.
41. Ferreira M.L.C.: Cognitive deficits in multiple sclerosis: a systematic review. Arq. Neuropsiquiatr. 2010; 68(4): 632-641.
42. Pittion-Vouyovitch S., Debouverie M., Guillemin F. et al.: Fatigue in multiple sclerosis is related to disability, depression and quality of live. J. Neurol. Sci. 2006; 243: 39-45.
43. Łabuz-Roszak B., Kubicka-Bączyk K., Pierzchała K. et al.: Jakość życia chorych na stwardnienie rozsiane – związek z cechami klinicznymi choroby, zespołem zmęczenia i objawami depresyjnymi. Psychiatr. Pol. 2013; 46(3): 433-442.
44. Paraprigopoulos T., Ferentinos P., Kouzoupis A. et al.: The neuropsychiatry of multiple sclerosis: Focus on disorders of mood, affect and behaviour. Int. Rev. Psychiatr. 2010; 22(1): 14-21.
45. Jason L., Evans M., Brown M. et al.: Fatigue Scales and Chronic Fatigue Syndrome: Issues of Sensitivity and Specificity. DSQ 2011; 31(1): 1375 (online).
46. Krupp L.B., La Brocca N.G., Muir-Nash J. et al.: The fatigue severity scale: Application to patients with multiple sclerosis and systemic lapus erythematosus. Arc. Neurol. 1989; 46: 1121-1123.
47. Rietberg M.B., Van Wegen E.E.H., Kwakkel G.: Measuring fatigue in patients with multiple sclerosis: reproducibility, responsiveness and concurrent validity of three Dutch self-report questionnaires. Disabil. Rehabil. 2010; 32(22): 1870-1876.
48. Bartosik-Psujek H.: Aktualne zasady terapii stwardnienia rozsianego. Aktualn. Neurol. 2009; 9(2): 126-131.
49. Metz L.M., Patten S.B., Archibald C.J. et al.: The effect of immunomodulatory treatment on multiple sclerosis fatigue. J. Neurol. Neurosurg. Psychiatry 2004; 75(7): 1045-1047.
50. Ziemssen T.: Multiple sclerosis beyond EDSS: depression and fatigue. J. Neurol. Sci. 2009; 277(supl. 1): S37-41.
51. Jongen P.J., Lehnick D., Koeman J. et al.: Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study. J. Neurol. 2014; 261: 1469-1476.
52. Wilken J., Kane R.L., Sullivan L. et al.: Changes in fatigue and cognition in patients with relapsing forms of multiple sclerosis treated with natalizumab. Int. J. MS Care 2013; 15(3): 120-128.